RxDoctor Payments Data

Kiho Min, MD

Family Medicine · Fairfax, VANPI 1881649424

Payments from drug & device makers

$1,087in general payments, 2019–2025

Across 30 payments — averaging $36.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$289
  • Novo Nordisk$178
  • Amarin Pharma, Inc.$143
  • Dexcom, Inc.$142
  • Merck$103
  • Gilead$57
  • plus $175 from 6 others

What the payments were for

  • Food & beverage$1,087100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,087 in reported general payments places this provider in the 65th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$98,970
Medicare patients
178
Services billed
797

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf)Adalimumab12$83,496
EliquisApixaban36$56,310
ProliaDenosumab32$55,560
JardianceEmpagliflozin31$51,090
OzempicSemaglutide19$47,264
JanumetSitagliptin Phos/Metformin Hcl28$45,731
TradjentaLinagliptin30$44,994
JanuviaSitagliptin Phosphate31$37,809
Janumet XrSitagliptin Phos/Metformin Hcl27$29,203
VemlidyTenofovir Alafenamide13$18,439
MyrbetriqMirabegron12$17,373
VascepaIcosapent Ethyl18$12,869
Omega-3 Acid Ethyl Esters43$10,763
Breo ElliptaFluticasone/Vilanterol17$10,754
Dexlansoprazole DrDexlansoprazole21$8,915

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet, Januvia, Janumet Xr$103$112,74486 claims
PfizerEliquis$22$56,31036 claims
AmgenProlia$289$55,56032 claims
Novo NordiskOzempic$178$47,26419 claims
GileadVemlidy$57$18,43913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →